What MUMS means
FDA’s Minor Use and Minor Species program addresses drugs for minor species and for minor uses in major species. A minor use can include an uncommon disease in a major species such as dogs, cats, cattle or chickens.
The framework matters because traditional drug-development economics become difficult when the potential patient population is limited.
Incentives can reduce—not erase—development risk
FDA programs may provide mechanisms such as designation incentives and pathways tailored to eligible uses. In 2026, CVM released a MUMS Blueprint for Success for 2026–2028 aimed at modernizing and expanding the program.
These mechanisms do not turn a weak product into a strong one. The company still needs a meaningful clinical problem, feasible evidence generation, manufacturing capability and a commercial strategy.
Small markets can have concentrated value
Veterinary specialty care can make certain rare conditions easier to reach through referral networks. A company may also build scientific expertise or a platform that expands into adjacent indications after the first approval.
The investable question is whether the first market is large enough to support development and whether success creates additional options.
Diligence should model the real patient funnel
Start with disease incidence, diagnosed patients, treatable patients, access to specialists, expected price, duration of therapy and realistic adoption. Avoid multiplying the total pet population by a tiny assumed market share.
A smaller, well-defined funnel can be more useful than a large top-down estimate.
Primary resources
- FDA – Minor Use/Minor Species
- FDA – MUMS Blueprint for Success 2026–2028